Creso Pharma Limited
COPHFOTCHealthcare
$0.12
+$0.00(+0.00%)
Market Cap$131722112
P/E Ratio—
52W High—
52W Low—
Creso Pharma Limited (COPHF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · COPHF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $18.92M | $8.69M | $6.22M | $2.45M | $3.63M |
| Cost of Revenue | $16.59M | $8.40M | $6.62M | $6.33M | $1.50M |
| Gross Profit | $2.33M | $0.29M | ($0.40M) | ($3.88M) | $2.13M |
| Gross Margin %(computed) | 12.34% | 3.30% | -6.44% | -158.61% | 58.62% |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $0.00M | $0.00M | $0.34M | $0.29M |
| G&A Expenses | $5.26M | $6.21M | $4.35M | $3.26M | $5.64M |
| Total Operating Expenses | $2.33M | $19.48M | $27.95M | $10.49M | $12.30M |
| Operating Income | ($16.68M) | ($19.57M) | ($28.32M) | ($16.84M) | ($10.21M) |
| Operating Margin %(computed) | -88.16% | -225.19% | -455.50% | -687.95% | -281.51% |
| Interest Income | $0.68M | $0.08M | $0.00M | $0.00M | $0.06M |
| Interest Expense | $9.69M | $0.69M | $1.71M | $9.27M | $2.09M |
| Income Before Tax | ($35.52M) | ($32.78M) | ($30.03M) | ($30.78M) | ($15.34M) |
| Income Tax Expense | ($0.00M) | $0.00M | $1.73M | $6.80M | $1.71M |
| Net Income | ($52.45M) | ($32.78M) | ($31.77M) | ($37.58M) | ($17.05M) |
| Net Margin %(computed) | -277.18% | -377.28% | -510.84% | — | -470.25% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.00 | $-0.02 | $-0.03 | $-0.10 | $-0.12 |
| Wtd Avg Shares | 0.00M | 1463.48M | 1107.29M | 370.84M | 143.78M |
| EBITDA | ($25.16M) | ($17.62M) | ($28.06M) | ($16.49M) | ($9.81M) |
| EBITDA Margin %(computed) | -132.96% | -202.76% | -451.22% | -673.55% | -270.44% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · AUD · M
Explore more Creso Pharma Limited data
About Creso Pharma Limited (COPHF) Income Statement
Creso Pharma Limited (COPHF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, COPHF reported revenue of $0.02B, gross profit of $0.00B (gross margin 12.34%), and net income of ($0.05B) — a net profit margin of -277.18%.
Frequently asked questions
COPHF · 4 questionsCreso Pharma Limited (COPHF) reported revenue of $0.02B for 2023, up 117.8% year-over-year.
COPHF revenueCOPHF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09